Corporate News

2024

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2023

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2022

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2021

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2020

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2019

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

2018

Total Voting Rights

31 March 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 114,670,610 ordinary shares of £0.00037 each.

The total issued share capital of the Company consists of 114,670,610 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893
/ +44 (0)7879 741 001

 

Investor Alert

Sign up for Email Alerts